Hepatitis A Vaccine
Conditions
Keywords
Hepatitis A Vaccine, Immunogenicity, Safety
Brief summary
This is a Phase Ⅲ, open-label, single arm design combined with randomized, double-blind, active-controlled design trial to assess the immunogenicity and safety of different specifications of Healive® (the 0.5 mL pediatric dosage and the 1 mL adult dosage). A total of 680 healthy participants aged 1 year and above will be enrolled, including 200 participants aged 16 years and older (adult dose group), and 480 participants aged 1 to less than 16 years (pediatric dose group). For the adult dose group: open-label, single-arm design, 200 participants aged 16 years and above will be enrolled to receive Healive® (1.0 mL). For the pediatric dose group: double-blinded, randomized, positive-controlled design, 480 participants aged 1 to less than 16 years will be enrolled, and randomized in a 2:1 ratio to receive either Healive® (0.5 mL) or Avaxim® (0.5 mL). All participants will receive two doses of either Healive® or Avaxim® at 0 and 6 months.
Interventions
BIOLOGICALInactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)
Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, adult dose (≥ 16 years)
BIOLOGICALInactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL)
Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, pediatric dose (1\~\<16 years)
BIOLOGICALHepatitis A vaccine (inactivated, adsorbed)
Hepatitis A vaccine (inactivated, adsorbed) manufactured by Sanofi
Sponsors
Sinovac Biotech Co., Ltd
DUC MINH MEDICAL JSC.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy participants aged 1 year and older; 2. Participants (and/or their legal guardians) are able to understand and sign the informed consent voluntarily; 3. Participants of reproductive potential and their sexual partners should voluntarily use effective contraception from signing the ICF to 30 days after the second vaccination and avoid donating sperm or eggs. 4. Participants should provide verifiable identification, to be contacted, and to contact the investigator during the study period. 5. Participants should agree to comply with the lifestyle precautions outlined in the protocol.
Exclusion criteria
1. Prior vaccination with any hepatitis A vaccine or combined vaccines containing HAV components; 2. Prior history of HAV infection; 3. Female participants of reproductive potential who are pregnant (including a positive urine pregnancy test) or have a pregnancy plan within 30 days after the second vaccination, or who are currently lactating; 4. Known allergy to vaccines or vaccines ingredients; 5. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection); 6. Coagulation disorders (e.g. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture; 7. Poorly controlled chronic illnesses or history of severe diseases that, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, and a history of major organ transplantation; 8. Current or history of severe neurological diseases \[epilepsy, convulsions or seizures (excluding history of febrile seizures)\] or psychiatric disorders, or presence of a family history of psychiatric disorders; 9. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥20mg/day, or prednisone ≥2mg/kg/day, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment during the trial; 10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the trial; 11. Receipt of other investigational drugs/vaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period; 12. Receipt of attenuated live vaccines or nucleic acid vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening; 13. Fever on vaccination day, with axillary temperature \>37.2°C pre-vaccination, or vital signs outside normal range, or failure to pass physical examination; 14. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with drug administration or observation of local reactions; 15. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections; 16. Any other factors considered by the investigator to make the participant unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate of anti-HAV antibodies | 30 days after the second vaccination | The seroconversion rate of anti-hepatitis A virus (HAV) antibodies 30 days after the second vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seropositive rate of anti-HAV antibodies | 30 days after the second vaccination | The seropositive rate of anti-HAV antibodies 30 days after the second vaccination |
| Geometric mean concentration (GMC) of anti-HAV antibodies | 30 days after the second vaccination | The geometric mean concentration (GMC) of anti-HAV antibodies 30 days after the second vaccination |
| Geometric mean fold rise (GMFR) of anti-HAV antibodies | 30 days after the second vaccination | The geometric mean fold rise (GMFR) of anti-HAV antibodies 30 days after the second vaccination |
| Incidence of adverse events (AE)/adverse reactions (AR) | 30 days after each vaccination | Incidence of adverse events (AE)/adverse reactions (AR) within 30 days after each vaccination |
| Incidence of serious adverse events (SAE) | From first vaccination to 30 days after second vaccination | Incidence of serious adverse events (SAE) from first vaccination to 30 days after second vaccination |
Countries
Vietnam
Contacts
CONTACTVan Anh Thi Pham
Outcome results
None listed